| Detected | Trial | Change |
|---|---|---|
| 2026-07-31 | NCT06500273 Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL |
Trial sites expanded: 77 -> 82 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT06500273 | Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Large B-cell Lymphoma | Recruiting |
| Phase 1/2 | |||
| NCT04416984 | Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With… | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | Active, Not Recruiting |
| Phase 1 | |||
| NCT07085104 | A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR… | Systemic Lupus Erythematosus (With and Without Nephritis) | Recruiting |
| NCT04696731 | Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal… | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | Active, Not Recruiting |
| Not specified | |||
| NCT06925685 | Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product | Hematologic Malignancies | Enrolling by Invitation |